CD4 and neoplasm: Another study reported that pemetrexed (cisplatin is not contained) combined with PD-1/PD-L1 can inhibit tumor growth by activating and/or recruiting tumor-infiltrating CD4+ and CD8+ T lymphocytes, which provides references for the regulatory mechanisms of pemetrexed in improving the immune checkpoint block (ICB) of lung cancer (28).